影响脑型肾上腺脑白质营养不良异基因造血干细胞移植后结局的变量
一项纳入59例患者的观察性研究,中位移植年龄8岁,分析供者来源、供受者匹配、预处理方案及脑病分期对首次异基因造血干细胞移植结局的影响。早期脑病组4年无主要功能障碍且无需第二次移植的生存率显著高于晚期脑病组(66% vs 41%,P=0.015),移植相关死亡率两组差异未达统计学显著(7% vs 22%,P=0.094)。
要点
- 早期脑病组4年无主要功能障碍且无需二次移植生存率为66%,晚期脑病组为41%(P=0.015)。
- 移植相关死亡率早期脑病组7% vs 晚期脑病组22%,差异未达统计学显著(P=0.094)。
- 无关脐带血移植的植入失败发生率显著高于匹配亲缘供者(P=0.039),急性GVHD和植入失败发生率随预处理方案不同而变化。
核心结论
- 早期脑型肾上腺脑白质营养不良患者接受异基因造血干细胞移植可稳定神经功能并改善生存,但存在移植相关死亡、植入失败和移植物抗宿主病等风险。
- 早期脑病队列4年无主要功能障碍且无需第二次移植的生存率显著高于晚期脑病队列(66% vs 41%,P=0.015),早期脑病两个亚组间可比(P=0.991)。
研究设计与样本
- 观察性研究,纳入59例接受首次异基因造血干细胞移植的脑型肾上腺脑白质营养不良患者,移植时中位年龄8岁。
- 疗效分析纳入53例,按疾病类别分层:晚期脑病(Loes评分>9或神经功能评分NFS>1,n=16)、早期脑病1(Loes≤4且NFS≤1,n=24)、早期脑病2(Loes>4-9且NFS≤1,n=13)。
- 研究注册于clinicaltrials.gov,注册号NCT02204904。
主要发现
- 4年无主要功能障碍且无需第二次异基因造血干细胞移植的生存率:早期脑病组66% vs 晚期脑病组41%(P=0.015);早期脑病1组与早期脑病2组间可比(P=0.991)。
- 移植后24个月神经功能评分较基线的中位变化:早期脑病1组(n=13)为0,早期脑病2组(n=6)为0.5,晚期脑病组(n=4)为2.5;Loes评分较基线的中位变化分别为早期脑病1组0、早期脑病2组0、晚期脑病组3.0;早期脑病组移植后神经功能稳定程度大于晚期脑病组。
- 移植相关死亡率:早期脑病组7% vs 晚期脑病组22%,差异未达统计学显著(P=0.094)。
- 植入失败发生率:无关脐带血移植显著高于匹配亲缘供者(P=0.039)。
- 急性移植物抗宿主病和植入失败发生率随预处理方案不同而变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early cerebral adrenoleukodystrophy can stabilize neurologic function and improve survival but has associated risks including transplant-related mortality (TRM), graft failure, and graft-versus-host disease (GVHD). An observational study of 59 patients with median age at allo-HSCT of 8 years addressed impact of donor source, donor match, conditioning regimen, and cerebral disease stage on first allo-HSCT outcomes. Efficacy analyses included 53 patients stratified by disease category: advanced disease (AD; n = 16) with Loes score >9 or neurological function score (NFS) >1 and 2 early disease (ED) cohorts (ED1 [Loes ≤4 and NFS ≤1; n = 24] and ED2 [Loes >4-9 and NFS ≤1; n = 13]). Survival free of major functional disabilities and without second allo-HSCT at 4 years was significantly higher in the ED (66%) vs AD (41%) cohort (P = .015) and comparable between ED1 and ED2 cohorts (P = .991). The stabilization of neurologic function posttransplant was greater in the ED vs AD cohort, with a median change from baseline at 24 months after allo-HSCT in NFS and Loes score, respectively, of 0 and 0.5 in ED1 (n = 13), 0.5 and 0 in ED2 (n = 6), and 2.5 and 3.0 (n = 4) in AD cohort. TRM was lower in the ED (7%) compared with the AD (22%) cohort; however, the difference was not significant (P = .094). Transplant-related safety outcomes were also affected by transplant-related characteristics: graft failure incidence was significantly higher with unrelated umbilical cord grafts vs matched related donors (P = .039), and acute GVHD and graft failure incidences varied by conditioning regimen. This study was registered at www://clinicaltrials.gov as #NCT02204904.
引用
- Chiesa R, Boelens JJ, Duncan CN, et al. Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy. Blood Adv. 2022. PMID: 34781360. doi:10.1182/bloodadvances.2021005294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。